Today: 20 May 2026
Browse Category

NASDAQ:TVTX 24 December 2025 - 13 January 2026

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Ligand Pharmaceuticals shares fell 10.6% after the FDA extended its review of partner Travere’s Filspari label expansion, resetting the decision deadline to April 13. Travere shares dropped 19%. The FDA classified the latest filing as a “major amendment” but did not request new safety or manufacturing data. The broader biotech sector was little changed.
13 January 2026
···
Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

Travere Therapeutics shares fell 19% Tuesday after the FDA extended its review of Filspari for broader use in kidney disease, pushing the decision deadline to April 13. The stock hit an intraday low of $22.35 before recovering. Travere forecast $127 million in Q4 U.S. net product sales and ended 2025 with $323 million in cash and equivalents. Analyst Joseph Schwartz warned a formal rejection from the FDA remains possible.
13 January 2026
··
Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

Travere Therapeutics shares dropped 5.3% to $36.09 Tuesday ahead of the FDA’s Jan. 13 decision on expanding kidney drug Filspari’s label. Options trading surged, with heavy put activity at the $35 strike. Chief Medical Officer Jula Inrig disclosed a planned sale of 15,000 shares to cover taxes. CEO Eric Dube will present at the J.P. Morgan Healthcare Conference on Jan. 12.
6 January 2026
··
Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

Travere Therapeutics shares fell 3.8% to $37.39 Tuesday afternoon, outpacing declines in biotech ETFs. SEC filings showed Chief Medical Officer Jula Inrig and Chief Commercial Officer Pieter Heerma sold shares on Dec. 24 under pre-arranged 10b5-1 plans. The moves come weeks before a key FDA decision on Filspari for FSGS, set for Jan. 13, 2026. Trading volume reached about 893,000 shares.
30 December 2025
Travere Therapeutics (TVTX) Stock Watch: Pre‑Market Focus on the Jan. 13 FDA Decision After a 14% Rally

Travere Therapeutics (TVTX) Stock Watch: Pre‑Market Focus on the Jan. 13 FDA Decision After a 14% Rally

Travere Therapeutics shares closed at $40.28 on Dec. 24, up 13.9% after bullish analyst commentary and anticipation of an FDA decision on FILSPARI for FSGS by Jan. 13, 2026. Early pre-market trading Friday showed TVTX around $40.6. The FDA dropped plans for an advisory committee meeting, which some investors see as a positive sign. Trading volume remains light due to the holiday.
26 December 2025
Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets

Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets

Travere Therapeutics shares jumped about 15% to over $40 in early trading on Dec. 24, 2025, hitting new highs during a holiday-shortened session. The surge followed investor anticipation of an FDA decision on FILSPARI for FSGS, expected by Jan. 13, 2026. No company news was released that day. The FDA previously waived an advisory committee review for the application.
24 December 2025
·

Stock Market Today

  • Agnico Eagle Mines Sees Rising Costs Despite Strong Q1 Earnings
    May 20, 2026, 9:10 AM EDT. Agnico Eagle Mines Limited (AEM) reported strong first-quarter earnings driven by higher gold prices. However, rising costs remain a concern. The company's all-in sustaining cost (AISC) rose 26% year-over-year to $1,483 per ounce, driven by higher cash costs and sustaining capital expenditure. Agnico Eagle forecasts further cost increases for 2026, with AISC expected between $1,400 and $1,550 per ounce. This inflationary pressure, including higher labor, electricity, and royalty costs, may weigh on profitability. Among peers, Barrick and Kinross Gold also project significant cost rises. AEM shares have gained 8.4% over six months but trade at a 22.9% premium to industry average. Earnings estimates for 2026 show a 58.7% rise but are trending lower, leading to a Zacks Rank of #3 (Hold).

Latest articles

NextNRG Shares Double as Record April Sales Drive Gains

NextNRG Shares Double as Record April Sales Drive Gains

20 May 2026
NextNRG Inc. shares fell to $0.73 in premarket trading Wednesday after doubling Tuesday, as investors reacted to record April revenue of $9.4 million and a 64% jump in gross profit. The company reported just $208,048 in cash at March 31 and is seeking new capital. Net loss for the first quarter widened to $10.8 million despite higher sales. Results are preliminary and unaudited.
GCL Global up after ADATA invests $10M; Nasdaq $1 rule still ahead

GCL Global up after ADATA invests $10M; Nasdaq $1 rule still ahead

20 May 2026
GCL Global Holdings said ADATA invested another $10 million in its 4Divinity unit, bringing total disclosed ADATA commitments since December to $23 million. GCL shares traded at about 80 cents in U.S. premarket, up from Tuesday’s 43-cent close, but still below Nasdaq’s $1 minimum bid rule, which it must meet by Sept. 14.
Analog Devices heads into AI test after record quarter, $1.5 billion deal

Analog Devices heads into AI test after record quarter, $1.5 billion deal

20 May 2026
Analog Devices reported fiscal second-quarter revenue up 37% to $3.62 billion, beating estimates, with adjusted EPS at $3.09. The company forecast third-quarter revenue of $3.9 billion, above Wall Street expectations, and announced a $1.5 billion cash deal to acquire Empower Semiconductor to expand in AI power delivery.
Go toTop